Amarna Therapeutics

Netherlands
Leiden, South Holland, The Netherlands, 2333

Company profile

Amarna Therapeutics company profile

Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2008-01-01, Year

Headquarters

Postal code
2333
Country code
NL
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
4
Total equity funding
$15.6M
Last funding
Grant / 2022-01-11
Last equity funding
Series Unknown / $4.5M
Investors
5
Lead investors
4
Founders
2
Articles
22

Founders and investors

Founders

Ben van LeentPeter de Haan

Lead investors

EurostarsFlerie InvestNetherlands Enterprise AgencyPim Berger

Investors

C4 VenturesEurostarsFlerie InvestNetherlands Enterprise AgencyPim Berger